Aortic & peripheral vascular diseaseCohort study
Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease
- Prospective nonrandomized trial
- multicentre
- propensity-score matched
Authors' conclusion
LD-DCBs demonstrate efficacy and safety comparable with HD-DCBs in patients with complex clinical backgrounds
Study context
- Population
- Patients undergoing endovascular therapy for symptomatic femoropopliteal artery disease (Rutherford classes 2–5)
- Participants
- 581 patients · 163 matched pairs
- Exposure
- Low-dose DCB vs high-dose DCB
- LD-DCBn = 370
- HD-DCBn = 211reference
- Outcome
- Primary patency of LD-DCB vs HD-DCB, by propensity score matching
- Follow-up
- 1 year
Main finding
1-year primary patency
Hazard ratio
0.93
95% CI 0.55–1.59
P = 0.79
By group
LD-DCB vs HD-DCB
HR 0.93 (95% CI 0.55–1.59); P = 0.79
As reported in the abstract
Observational data: associations, not effects.
Further findings
Interaction of baseline characteristics with 1-year restenosis risk
- No baseline characteristic had a significant interaction effect
Safety
| Outcome | LD-DCB | HD-DCB | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| Impaired flow after DCB application · matched population | 13.6% | 9.8% | 1.46 (0.78–2.73) | P = 0.24 | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Low-Dose vs High-Dose Drug-Coated Balloon for Symptomatic Femoropopliteal Artery Disease. JACC Cardiovasc Interv. Published 4 October 2023. doi:10.1016/j.jcin.2023.08.022
Summarised from the published abstract; every number is checked against it